文献速递银屑病与炎症性皮肤病

生物制剂真实世界使用者是否符合III期临床试验入组标准:PSOBIOTEQ队列研究

Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-17

共纳入1267例,993例(78.4%)不符合至少一项随机对照试验标准,251例(19.1%)不满足PASI/PGA严重度要求。符合者不良事件发生率显著低于不符合者(发生率比0.78,95%CI 0.62-0.97,P=0.03),两组药物存活无差异。

要点

  • 真实世界生物制剂使用者中78.4%不符合至少一项III期试验入组标准
  • 除疾病严重度外,最常见排除原因为非斑块状银屑病、显著心脏病和肝病
  • 不符合试验标准者不良事件发生率更高,提示试验结果外推需谨慎

核心结论

  • PSOBIOTEQ真实世界注册中大多数接受生物制剂治疗的患者不符合中重度银屑病III期试验入组标准。
  • 不符合III期试验标准的患者不良事件发生率更高。

研究设计与样本

  • 队列研究,将阿达木单抗REVEAL、乌司奴单抗PHOENIX、布罗达鲁单抗AMAGINE、司库奇尤单抗FIXTURE的III期试验入排标准应用于PSOBIOTEQ前瞻性注册队列。

主要发现

  • 993例(78.4%)不符合至少一项随机对照试验标准,251例(19.1%)不满足PASI/PGA严重度要求。
  • 除疾病严重度外,常见排除标准包括非斑块状银屑病(12.6%)、显著心脏病(8.4%)、显著肝病(7.3%)、肝酶升高(4.9-9.6%)及糖尿病个人史(9.2%)。
  • 符合与不符合标准的两组间药物存活无差异。
  • 符合标准者不良事件发生率显著低于不符合者,发生率比为0.78(95%CI 0.62-0.97,P=0.03)。

临床怎么用

  • 临床解读银屑病生物制剂III期试验结果时,需考虑真实世界中有大量患者不符合入组标准。
  • 对不符合试验标准的患者(如合并显著心肝疾病或糖尿病),应加强不良事件监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous inclusion and exclusion criteria are involved in phase III moderate to severe psoriasis trials investigating the safety and efficacy of biologics. This questions the generalization of results. METHODS: In this cohort study, we applied inclusion/exclusion criteria for phase III trials from original protocols (adalimumab - REVEAL, ustekinumab - PHOENIX, brodalumab - AMAGINE, secukinumab FIXTURE) to all patients enrolled in the PsoBioTeq prospective registry who received a biological agent for the first time between July 2012 and November 2017. We then compared the efficacy, drug survival and occurrence of adverse events between patients who satisfied/did not satisfy the eligibility criteria for these phase III trials. RESULTS: A total of 1267 patients were enrolled, of whom 993 (78.4%) were not eligible for at least one RCT (randomized controlled trial) and 251 (19.1%) did not meet the PASI/PGA severity requirements. Apart from disease severity, the most frequent criteria resulting in exclusion were as follows: non-plaque psoriasis (12.6%), significant cardiac disease (8.4%), significant liver disease (7.3%), elevated liver enzymes (4.9-9.6%) and personal history of diabetes (9.2%). There was no difference in drug survival between the two groups. The incidence ratio of adverse events was significantly lower in eligible versus non-eligible patients [0.78 (95% CI 0.62-0.97) (P = 0.03)]. CONCLUSION: The majority of patients treated with biologics in the PsoBioTeq real-life registry would not have been eligible for phase III moderate to severe psoriasis trials. Patients not eligible for psoriasis phase III clinical trials have a higher incidence of adverse events.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2019. PMID: 31419355. doi:10.1111/jdv.15878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。